The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

A new innovative tool forecasts the severity of a patient’s diagnosis and its likelihood of recurrence. This latest ...

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer ...

Or, if aggressive cancer features are identified later on through tumor testing called biomarker testing, like HER2 neu expression testing for breast cancer cells, explains Dr. Monique Gary ...

The universal cell-cycle inhibitor p21 Cip1/WAF1 is phosphorylated and localized in the cytoplasm in Her2/neu-overexpressing breast cancers as a result of its physical association with the ...

In close collaboration with the lab of Nai-Kong Cheung at MSK and Dane Wittrup at MIT, we have successfully applied this platform in three preclinical tumor models: GPA33 antigen (colorectal cancer); ...

BMBC is common in patients negative for estrogen/progesterone receptors and over-expressing epidermal growth factor receptor1 or 2 (EGFR or HER2/neu). However, both traditional and recent therapies ...

The phosphorylation of protein kinases leads to the activation of signal-transduction pathways, which have a critical role in a variety of biologic processes, including cell growth ...

Unlike other breast cancers, TNBC is challenging to treat because its tumor cells lack estrogen receptors, progesterone receptors, and high levels of HER2/neu protein, according to experts at the ...

Researchers have developed a new mechanism for predicting the aggressiveness of triple-negative breast cancer (TNBC). This ...